Skip to main content
. 2021 Sep 15;13(9):10094–10111.

Figure 6.

Figure 6

CAFs-derived exosomes transfer SNHG17 to osteosarcoma cells. (A) The size distribution of the isolated exosomes was detected by NTA. (B) Western blotting analysis for exosomal markers CD63 and CD9 of tumor cells and exosomes derived from CAFs. (C) The expression level of LncRNA SNHG17 in the exosomes derived from normal fibroblast and CAF of five pairs of clinical samples. **P<0.01, ***P<0.001 vs. the NFs-exosomes group. (D) The expression level of LncRNA SNHG17 in the HOS cells after treatment with exosomes derived from NFs or CAFs of three pairs of clinical samples. ***P<0.001. (E) Cells were treated by PBS, NFs-exosomes, or CAFs-exosome, and the cell viability was determined by CCK-8 assay. (F) The colony assay and (G) migration assay of SJSA-1 and HOS cells after different treatments were performed. Bar = 20 μm. *P<0.05, **P<0.01, ***P<0.001 vs. the sh-NC group. #P<0.05, ##P<0.01, ###P<0.001 vs. the CAFs-exosome group.